Thiadiazoles are a subfamily of azoles. Structurally, they are five-membered heterocyclic compounds containing two nitrogen atoms and one sulfur atom, and two double bonds, forming an aromatic ring. Depending on the relative positions of the heteroatoms, there are four possible structures; these forms do not interconvert and are therefore structural isomers rather than tautomers. These compounds themselves are rarely synthesized and have no particular utility, however, compounds that use them as structural motifs are fairly common in pharmacology.
Dec 10, 2023, VEOZA (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause.
VEOZAH is the first and only neurokinin 3 (NK3) receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS. First-in-class fezolinetant brings women a new nonhormonal therapy for hot flashes.
In May 2023, FDA has approved VEOZA(fezolinetant) 45 mg once daily for the treatment of moderate to severe VMS due to menopause.
Search 
+86 21 5895 0110 
